<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141105">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01740583</url>
  </required_header>
  <id_info>
    <org_study_id>CLPR-007</org_study_id>
    <nct_id>NCT01740583</nct_id>
  </id_info>
  <brief_title>Mitralign Percutaneous Annuloplasty System for Chronic Functional Mitral Valve Regurgitation</brief_title>
  <acronym>ALIGN</acronym>
  <official_title>A Feasibility Study of the Mitralign Annuloplasty System for the Treatment of Chronic Functional Mitral Valve Regurgitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitralign, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitralign, Inc.</source>
  <oversight_info>
    <authority>Paraguay: Ministerio de Salud PÃºblica y Bienestar Social</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety and device performance of the Mitralign
      system (&quot;MPAS&quot;) to treat functional mitral valve regurgitation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ALIGN study is a single arm, prospective study.  The objective of the study is to
      investigate the safety and performance of a catheter-based plication device intended to
      reduce the circumference of the dilated mitral valve.  The study will enroll up to 50
      subjects from up to 5 sites (Paraguay, Columbia, Dominican Republic, Brazil, and India) who
      will be followed for 36 months post index procedure. Enrollment is defined at the time the
      study device is inserted into the body and patients will be followed at 30 days, and Months
      6, 12, 24 and 36  post index procedure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Major Adverse Events (MAE)</measure>
    <time_frame>within 30 days post procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>MAE defined as occurrence of any of the following: Mitral valve-related surgery/intervention, myocardial infarction, cardiac tamponade, stroke, device and/or procedure-related death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic Outcomes</measure>
    <time_frame>at 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Freedom from an increase in ventricular diameter</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Mitral Valve Regurgitation</condition>
  <arm_group>
    <arm_group_label>annuloplasty</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive treatment with the Mitralign Percutaneous Annuloplasty System (MPAS).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>percutaneous annuloplasty</intervention_name>
    <description>plication of the mitral valve annulus</description>
    <arm_group_label>annuloplasty</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NYHA II-IV

          -  Structurally normal mitral valve

          -  At least Grade 2 mitral regurgitation

          -  Left ventricular ejection fraction not less than 20% and not greater than 45%

          -  Left ventricular end diastolic diameter not less than 5.0 cm and not greater than 7.5
             cm

        Exclusion Criteria:

          -  Pregnant or lactating female

          -  Mitral stenosis

          -  Mod/severe aortic stenosis or regurgitation

          -  Mod/severe tricuspid stenosis or regurgitation

          -  Endocarditis

          -  Previous mitral valve repair or MV replacement

          -  Bioprosthetic or mechanical aortic valve

          -  Known unstable angina or MI within 30 days prior to procedure

          -  CVA within past 6 months

          -  Known contraindications to blood transfusion, contrast dye, DAPT
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Ebner, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sanatorio Italiano (The Italian Hospital)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emily Gmitter</last_name>
    <phone>978-863-2401</phone>
    <email>egmitter@mitralign.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jenifer Foss</last_name>
    <phone>978-863-2445</phone>
    <email>jfoss@mitralign.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sanatorio Italiano</name>
      <address>
        <city>Asuncion</city>
        <country>Paraguay</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Ebner, M.D.</last_name>
      <phone>011 595 21 296 727</phone>
      <email>adrian@ebner.com.py</email>
    </contact>
    <investigator>
      <last_name>Santiago Gallo, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Paraguay</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>December 4, 2012</lastchanged_date>
  <firstreceived_date>November 30, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mitral valve, regurgitation, annuloplasty</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
